| Q41660660 | "Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis |
| Q32174781 | Ammonium glycyrrhizin counteracts liver injury caused by lipopolysaccharide/amoxicillin-clavulanate potassium |
| Q44488879 | Antibodies to soluble liver antigen in patients with various liver diseases: a multicentre study |
| Q40367327 | Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment Challenges |
| Q89414799 | Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management |
| Q86886381 | Autoimmune hepatitis |
| Q36490242 | Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview |
| Q30276377 | Autoimmune-like drug-induced liver injury: a review and update for the clinician |
| Q40995506 | Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis |
| Q58691356 | Compound Ammonium Glycyrrhizin Protects Hepatocytes from Injury Induced by Lipopolysaccharide/Florfenicol through a Mitochondrial Pathway |
| Q49022529 | Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases |
| Q46213703 | Dealing with stress |
| Q50240021 | Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. |
| Q60343992 | Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge |
| Q33563872 | Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. |
| Q57126212 | Drug-induced cholestasis |
| Q30235089 | Drug-induced liver injury: recent advances in diagnosis and risk assessment |
| Q37356353 | Epidemiology and treatment of autoimmune hepatitis |
| Q28534593 | HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity |
| Q38838664 | Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions |
| Q39012464 | Hepatotoxicity of statins and other lipid-lowering agents |
| Q36796350 | Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs |
| Q51027472 | Natural history and outcomes in drug-induced autoimmune hepatitis. |
| Q33867410 | Ramipril-associated cholestasis in the setting of recurrent drug-induced liver injury |
| Q26864272 | Review article: the management of autoimmune hepatitis beyond consensus guidelines |
| Q53082472 | The value of eosinophil VCS parameters in predicting hepatotoxicity of antituberculosis drugs. |